Allogene Therapeutics, Inc. (ALLO) vs Aquestive Therapeutics, Inc. (AQST)
A side-by-side comparison of Allogene Therapeutics, Inc. and Aquestive Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALLO
Allogene Therapeutics, Inc.
$1.48HealthcareDelayed quote: Oct 6, 2026, 11:35 AM EDT
AQST
Aquestive Therapeutics, Inc.
$4.60HealthcareDelayed quote: Oct 6, 2026, 11:35 AM EDT
Total return — ALLO vs AQST
growth of $100 · dividends reinvested · last 8yALLO -94.0% (-29.6%/yr)AQST -68.3% (-13.4%/yr)AQST compounded faster over this window
Log scale — wide-divergence pair
ALLO AQST
ALLO vs AQST: by the numbers
- •AQST is the larger company ($577M vs $511M market cap).
- •Both run net losses; AQST's is the smaller (-144.63% vs -3566.68% net margin).
- •Both shrank revenue over the past five years; AQST's decline was smaller (-0.58% vs -34.47% CAGR).
Metrics side by side
Valuation
| Metric | ALLO | AQST |
|---|---|---|
| P/S ratio | 110.09 | 10.66 |
| P/B ratio | 1.17 | N/A |
Profitability
| Metric | ALLO | AQST |
|---|---|---|
| Gross margin | 0.00% | 67.04% |
| Operating margin | 0.00% | -156.36% |
| Net margin | -3566.68% | -144.63% |
| ROE | -37.94% | N/A |
| ROIC | -34.79% | -45.62% |
Growth (annualized)
| Metric | ALLO | AQST |
|---|---|---|
| Revenue CAGR (5Y) | -34.47% | -0.58% |
| Total return CAGR (5Y) | -42.72% | 2.24% |
Frequently asked
- Which has grown faster, ALLO or AQST?
- Neither grew: over the past five years both shrank revenue, with AQST's decline the smaller — ALLO at a -34.47% CAGR versus AQST at -0.58%.
- How have ALLO and AQST total returns compared?
- Over the past 5 years, ALLO delivered -42.72% and AQST delivered 2.24% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.